Patient
SITE003-0051
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE003 (CAN) (Dr. Okafor)
consented 2025-11-07
Adverse events
10
Serious AEs
0
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 10
Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 132); relationship: not assessed
Grade 1 Decreased appetite — outcome: UNKNOWN; onset 2022-08-24 (study day 106); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-16 (study day 98); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 94); relationship: not assessed
Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-08-10 (study day 92); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-06 (study day 57); relationship: RELATED
Grade 2 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-06-18 (study day 39); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-06-08 (study day 29); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-02 (study day 23); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-05-18 (study day 8); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.